• Services for Regulatory ATMP Development
    Services for Regulatory ATMP Development

    Living biotherapeutics - Oncolytic viruses - AAV vectors

  • ATMP Biodistribution and Shedding Analysis
    ATMP Biodistribution and Shedding Analysis

    qPCR - CFU determination - Flow cytometry - EliSpot

  • MultiPlex miRNA Biomarker Discovery
    MultiPlex miRNA Biomarker Discovery

    Hydrogel particle-based >65-plex from small samples amounts

  • MultiPlex miRNA Clinical Profiling
    MultiPlex miRNA Clinical Profiling

    Pre-designed & custom >65-plex panels

The best lessions are learned through experience. The Accelero team has been working on numerous non-clinical GLP and clinical GCP studies - from first-in-man (FIM) and phase 1 to global phase 3. Clients from seven European countries benefit from Accelero´s strong background in method setup and validation e.g. for regulatory Advanced Therapy Medicinal Products (ATMP) development.



See what kind of therapeutics Accelero has supported with its bioanalytical drug development expertise.

  • Human mesenchymal stem cells (non-clinical)
  • Genetically modified microbial cells (non-clinical)
  • Lyposomal siRNA formulation (non-clinical and clinical)
  • miRNA antagomir formulations (non-clinical)
  • RNA aptamer (non-clinical)
  • DNA aptamer (non-clinical and clinical)
  • DNA vaccine (non-clinical)
  • Oncolytic viruses (non-clinical and clinical)
  • Adeno-associated vectors (non-clinical)
  • Antibiotics (clinical)
  • Monoclonal antibodies (non-clinical)
  • Biosimilars (non-clinical)



Accelero´s clients may be active in the following therapeutic areas:

  • Cardiovascular diseases
  • Cancer immunotherapy
  • Cancer treatment
  • Autoimmune diseases
  • Wound healing
  • Sepsis
  • Antibiotics
  • Eye diseases



Please find below some examples for which Accelero has been selected as a bioanalytical service partner:

  • Pharmacokinetic characterization of drug substances and drug products in non-GLP dose range finding (DRF) studies in rodents, non-human primates, and minipigs (ELISA, qPCR).
  • GLP safety tox studies in rodents, non-human primates, hamsters, rabbits, and minipigs (ELISA, qPCR).
  • Plasmid GLP biodistribution in rodents and minipigs (qPCR).
  • Virus GLP biodistribution in hamsters (qPCR).
  • Shedding studies in minipigs (qPCR)



See where Accelero has a proven track record in serving biotechnology-driven clinical stage clients.

  • Pharmacokinetic characterization in first-in-man / phase 1 dose escalation studies (ELISA, qPCR).
  • Drug safety monitoring (ELISA), and accurately timed reporting to the Drug Safety Monitoring Board (DSMB).
  • Particle-based multiplex immunoassay for cytokine quantification in human serum, cerebrospinal fluid, and bronchoalveolar lavage (ELISA, hydrogel particle-based flow cytometry).
  • Micro-organism quantification in human sputum collected in global phase 3 studies (qPCR).



Accelero Bioanalytics GmbH is fully committed to the idea of strikt confidentiality. For this reason Accelero will never publish client information on any of the websites hosted by Accelero Bioanalytics GmbH. Accelero will not disclose any client details without written permission. If you are interested in learning more about Accelero´s international clients, please feel free to send an email request to service (at) accelero-bioanalytics.com. We will be delighted to evaluate your request.


Cookies user prefences
We use cookies to ensure you to get the best experience on our website. If you decline the use of cookies, this website may not function as expected.
Accept all
Decline all
Read more
Tools used to analyze the data to measure the effectiveness of a website and to understand how it works.
Google Analytics